CD33 and acute myeloid leukemia: Gemtuzumab ozogamicin (GO) is a first-generation ADC targeting CD33 on myeloid leukemia cells and the first to attain United States Food and Drug Administration (FDA) approval for adult patients with relapsed AML in 2000.